US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Vycor Medical, Inc.

0.1100

0.0000

Volume:21.80K

Turnover:2.28K

Market Cap:3.67M

PE:-10.77

High:0.1100

Open:0.1027

Low:0.0812

Close:0.1100

52wk High:0.5000

52wk Low:0.0511

Shares:33.37M

Float Shares:12.98M

Volume Ratio:5.52

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0102

EPS(LYR):-0.0789

ROE:45.31%

ROA:5.57%

PB:-0.91

PE(LYR):-1.39

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Vycor Medical Reports 31% Increase in Third-Quarter Revenue

NovaSource, an Affiliate of Clairvest Group Inc., Launches AI-Powered NovaVision Platform for Solar Optimization

Vycor Medical Inc. Reports 24% Revenue Increase and Break-Even EPS for Q2 2025, Achieves $23,887 Net Income

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/VYCO"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VYCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VYCO\",,,,,undefined,":{"symbol":"VYCO","market":"US","secType":"STK","nameCN":"Vycor Medical, Inc.","latestPrice":0.11,"timestamp":1771621200000,"preClose":0.11,"halted":0,"volume":21800,"delay":15,"changeRate":0,"floatShares":12983419,"shares":33372796,"eps":-0.010213,"marketStatus":"Pre-Mkt","change":0,"latestTime":"02-20 16:00:00 EST Delay","open":0.1027,"high":0.11,"low":0.0812,"amount":2282.66,"amplitude":0.261818,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.010213,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771857000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.11,"volumeRatio":5.518987411632752},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VYCO\",,,,,undefined,":{"symbol":"VYCO","floatShares":12983419,"roa":"5.57%","roe":"45.31%","lyrEps":-0.078879,"volumeRatio":5.518987411632752,"shares":33372796,"dividePrice":0,"high":0.11,"amplitude":0.261818,"preClose":0.11,"low":0.0812,"week52Low":0.05105,"pbRate":"-0.91","psRate":"1.93","week52High":0.5,"institutionHeld":0,"latestPrice":0.11,"eps":-0.010213,"divideRate":0,"volume":21800,"delay":15,"ttmEps":-0.010213,"open":0.1027,"prevYearClose":0.121,"prevWeekClose":0.11,"prevMonthClose":0.11,"prevQuarterClose":0.121,"fiveDayClose":0.11,"twentyDayClose":0.11,"sixtyDayClose":0.175},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VYCO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-13","symbol":"VYCO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-08-13","symbol":"VYCO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"VYCO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-13","symbol":"VYCO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699851600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2020-03-27","symbol":"VYCO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1585281600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VYCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VYCO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VYCO\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583688606","title":"Vycor Medical Reports 31% Increase in Third-Quarter Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2583688606","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583688606?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:25","pubTimestamp":1763137506,"startTime":"0","endTime":"0","summary":"Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDLwqWyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VYCO"],"gpt_icon":0},{"id":"2565684680","title":"NovaSource, an Affiliate of Clairvest Group Inc., Launches AI-Powered NovaVision Platform for Solar Optimization","url":"https://stock-news.laohu8.com/highlight/detail?id=2565684680","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565684680?lang=en_us&edition=fundamental","pubTime":"2025-09-08 21:01","pubTimestamp":1757336504,"startTime":"0","endTime":"0","summary":"NovaSource Power Services, an affiliate of Clairvest Group Inc., has launched NovaVision, an AI-powered platform aimed at optimizing utility-scale solar and energy storage assets. As the world's largest solar operations and maintenance provider, NovaSource introduces this solution to enhance asset performance through predictive capabilities such as performance monitoring, anomaly detection, and guided resolution. NovaVision integrates advanced analytics and real-time intelligence to help asset owners bridge the gap between expected and actual performance, thereby maximizing energy output. Key features include 360° site visibility for improved decision-making and a robust analytics engine for early detection of inverter performance issues. These innovations are set to streamline operations, reduce downtime, and boost ROI for solar and storage portfolios.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL14jX3H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","VYCO"],"gpt_icon":0},{"id":"2558764625","title":"Vycor Medical Inc. Reports 24% Revenue Increase and Break-Even EPS for Q2 2025, Achieves $23,887 Net Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2558764625","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558764625?lang=en_us&edition=fundamental","pubTime":"2025-08-09 00:49","pubTimestamp":1754671763,"startTime":"0","endTime":"0","summary":"Vycor Medical Inc. has reported its financial results for the three and six months ending June 30, 2025. The company experienced a notable increase in revenue, with the Vycor Medical division seeing a 24% rise in revenue for the three-month period and a 28% increase for the six-month period, primarily driven by growth in international markets. For the three months ended June 30, 2025, Vycor Medical reported revenue of $496,353, up from $406,278 in the same period of 2024. The gross profit for the same period rose to $415,271 from $371,115. For the six months ended June 30, 2025, revenue increased to $932,731 compared to $743,246 in the prior year, with gross profit rising to $773,805 from $671,077. The company posted a GAAP net income of $23,887 for the three-month period, with an operating profit of $51,146. Vycor Medical's non-GAAP operating profit for the same period was $84,481, reflecting a significant increase over the 2024 periods. Vycor Medical has also expanded its internation","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL54xrs6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYCO"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VYCO\",params:#limit:6,delay:false,,,undefined,":[]}}